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ABVD   adriamycin, bleomycin, vinblastine and dacarbazine 
AML   acute myeloid leukemia 
ANC   absolute neutrophil count 
ASCT   autologous stem cell transplantation 
A. xylosoxidans Achromobacter xylosoxidans 
BC   blood culture 
B. cepacea  Burkholderia cepacea 
BEAM BiCNU®, etoposide, cytosine-arabinoside, melphalan 
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BSIs bloodstream infections 
CDI   Clostridium difficile infection 
CDV   cidofovir 
CLABSI  central line-associated bloodstream infection 
CLL   chronic lymphocytic leukemia 
CMV   cytomegalovirus 
CNS   coagulase-negative staphylococci 
CSF   cerebrospinal fluid 
CT   computed tomography 
CVCs   central venous catheters 
CVID   common variable immunodeficiency syndrome 
Dex   dexamethasone 
DHAP   dexamethasone, cisplatin, cytarabine 
dsDNA   double-stranded DNA 
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E. coli    Eschericia coli 
ELISA   enzyme-linked immunosorbent assay 
ESBLs   extended-spectrum beta-lactamases 
FN   febrile neutropenia 
F. nucleatum  Fusobacterium nucleatum 
FUO   fever of unknown origin 
GCV   ganciclovir 
HHV-1   human herpesvirus 1 or herpes simplex 1 (HSV-1) 
HHV-2   human herpesvirus 2 or herpes simplex 2 (HSV-2) 
HHV-3   human herpesvirus 3 or varicella-zoster virus (VZV) 
HHV-4   human herpesvirus 4 or Epstein-Barr virus (EBV) 
HHV-5   human herpesvirus 5 or cytomegalovirus (CMV) 
HHV-6   human herpesvirus 6 
HHV-7   human herpesvirus 7 
HHV-8 human herpesvirus 8 or Kaposi sarcoma-associated herpesvirus (or KSHV) 
HL Hodgkin lymphoma 
HSCT   haematopoietic stem cell transplantation 
HSV   herpes simplex virus 
IgM, IgG  immunoglobulin M, immunoglobulin G 
MDI   microbiologically documented infection 
MM   multiple myeloma 
MRI   magnetic resonance imaging 
MRSA   methicillin resistant Staphylococcus aureus 
NHL   non-Hodgkin lymphoma 
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N. farcinica  Nocardia farcinica 
P. aeruginosa  Pseudomonas aeruginosa 
PCRs   polymerase chain reactions 
RBCs   red blood cells 
R-FC   rituximab + fludarabine + cyclophosphamide 
RSV   respiratory syncytial virus 
SAA   severe aplastic anaemia 
S. aureus  Staphylococcus aureus 
SCT   stem cell transplantation 
S. pneumoniae  Streptococcus pneumoniae 
Thal   thalidomide 
TNF   tumour necrosis factor 
VGC   valganciclovir 
VRE   vancomycin resistant enterococci 
WBCs   white blood cells 
WHO   World Health Organization 
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1. INTRODUCTION 
1.1. INFECTIOUS COMPLICATIONS IN PATIENTS WITH HAEMATOLOGICAL 
DISORDERS 
During the past few decades, significant developments have occurred in the treatment 
of malignant diseases and, because of these, the cancer-related death rate is decreasing [86]. 
Haematopoietic stem cell transplantation (HSCT) has been incorporated into the consolidating 
treatment of different types of lymphoproliferative disorders in an autologous setting, or 
allogeneic stem cell transplantation, as curative intent for acute leukaemias [85]. However, 
mainly because of the better immunosuppressive effects of these new drugs, neutropenia 
remains one of the most serious side effects of antineoplastic treatments [85]. Neutropenia 
may be associated with the malignancy itself or it may be present as a consequence of 
chemotherapy and this is the major risk factor for developing infectious complications in this 
patient group. The role of neutropenia in infections was recognised in the 1960’s [15]. The 
majority of patients (about 30-60%) with neutropenia develop infectious complications and 
13-37% of them may develop bacteremia [110, 112, 78, 93]. The most common sites and 
organs of infections in neutropenic patients are the respiratory tract (35-40%), (paranasal 
sinuses and lung infiltration), and bacteremia (15-35%), (central line-associated bloodstream 
infection, CLABSI). Skin, soft tissues and urinary tract are involved in 5-10% of cases, and 
also infections originating from the gastro-intestinal tract (neutropenic enterocolitis and 
perianal inflammation) and oro-pharynx occur in 5-10% of cases [85, 46]. 
The widespread use of more aggressive chemotherapy, and introduction of monoclonal 
antibodies and biological therapy in the treatment of malignant haematological diseases have 
produced a persistent and worsening immune-deficient state, and this may also contribute to 
the development of various infections. During the hospitalisation of these patients, the 
spectrum of colonising microorganisms on the skin and mucosal surfaces has radically 
changed because of therapeutic, surgical and other invasive interventions, hence the 
colonisation resistance of the normal flora has decreased [77, 47, 49]. In the majority of 
microbiologically documented infections in patients with cancer, the causative 
microorganisms are part of the endogenous flora. Only in a few cases might the infection arise 
from exogenous sources. Because of the above-mentioned factors, bacterial, viral and fungal 
infections are important causes of morbidity and mortality for patients with malignancies 
(Fig. 1) [111]. 
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Figure 1. Increase in mortality rates among patients with cancer owing to various infections (source: Kuderer 
NM et al.: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. 
Cancer. 2006 May 15;106(10):2258-66.) 
The spectrum of pathogens causing infections in this patient group is constantly changing, and 
it is influenced by various factors including local epidemiology, the use of antibiotics, 
antiviral and antifungal agents, the use of catheters and various medical devices [85]. Viral 
infections are the most common cause of morbidity in cancer patients especially among 
pediatric patients. Viruses directly affect the cell-mediated immune system, thus they increase 
the risk of developing serious and life threatening infections. In the case of viral infections, 
the most important pathogens are the cytomegalovirus (CMV), herpes simplex virus (HSV), 
varicella-zoster virus (VZV), respiratory syncytial virus (RSV), parainfluenza and influenza 
viruses, the human herpesvirus 6 (HHV-6), human poliomavirus 1 (BK virus), adenovirus and 
the human metapneumovirus. Regarding bacterial infections in patients with haematologic 
malignancy, the results of various international surveys are available. Earlier, mainly Gram-
negative bacteria could be detected from infectious complications, while nowadays, Gram-
positive bacteria are frequently associated with sepsis in this patient group and the role of 
atypical mycobacteria, intracellular pathogens and opportunistic bacteria is becoming 
evermore important due to developments in microbiological methods. The significance of 
bacterial infections in patients with haematologic malignancy is well characterised, while the 
incidence and consequence of viral infections are poorly described in the non-transplant 
haematologic patient group. 
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1.1.1. Bacterial infections in patients with haematologic diseases 
In recent years cancer-related mortality has decreased substantially in patients with 
malignant haematological diseases because of the use of modern chemotherapeutic drugs, 
monoclonal antibodies, and stem cell transplantation (SCT). In spite of this, infectious 
complications such as bloodstream infections (BSIs) are major causes of morbidity and 
mortality among these patients [77, 36]. In the nineteenth century, the relevance of infection 
in morbidity and mortality of patients with acute leukaemia had already been described, while 
the role of neutropenia in infection was only recognised in the 1960’s. Febrile neutropenia 
(FN) is one of the most important complications in patients undergoing anticancer therapy 
[93, 76]. During a neutropenic episode, a fever developed in 80% of patients with malignant 
haematological diseases [64, 46]. The occurrence of BSIs at the onset of FN accounts for 10-
25 % of all febrile events. This incidence is higher (13-60%) in haematopoietic transplant 
recipients. In the 1960s and 1970s, BSIs mainly were caused by Gram-negative bacteria. In 
the mid-eighties, changes were observed in the spectrum of pathogens associated with 
bloodstream infections from Gram-negatives to Gram-positives because of the widespread use 
of fluoroquinolone prophylaxis [50, 119, 110, 103], the wide range of applications of central 
venous catheters (CVCs), severe mucositis and prolonged neutropenia associated with 
intensive chemotherapeutic regimens [50]. 
Patients with acute leukemia may have a high risk of infection as a consequence of both 
leukemic cell proliferation and infiltration in the bone marrow, and anti-leukemic treatment. 
Complete remission may be achieved with intensive chemotherapy in 80% of patients with 
AML (acute myeloid leukemia) below 60-65 years of age, and nearly 40% of cases may be 
cured with intensive post-remission consolidating therapy [22, 65]. The treatment regimens, 
mainly in patients with AML during and after the first course of induction therapy may 
produce long-lasting neutropenia that predisposes patients to infections [78]. The rate of 
infections increases with the severity and duration of neutropenia [36]. Probably more than 
90% of febrile neutropenic episodes in AML patients are caused by infection. Madani et al. 
identified the site of infections in 81% of febrile events. Among neutropenic patients with 
AML, the rate of BSI was 37.8%, and 75.8 % of it was caused by Gram-positive cocci, while 
only 12.1% of BSIs were caused by Gram-negative bacilli [77]. There are several risk factors 
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for infections, which may present simultaneously, such as an injury of the normal muco-cutan 
barrier (mucosal surface and skin) and the use of intravascular catheters. On the basis of the 
predisposing factors and local epidemiologic data, the spectrum of the possible pathogens is 
already taking shape. At the same time, the use of antibiotic therapy with different indications 
(prophylactic, empiric or targeted therapy) has also had an impact on the selection of the 
spectrum of the pathogen and bacterial resistance [63]. Bacterial infections are frequently 
detected early in the neutropenic phase, while fungal infection occurs when the neutropenia is 
prolonged. The spectrum of pathogens and its epidemiology occasionally vary in this patient 
group, hence it is a good idea to survey local epidemiological data [97, 82]. 
Infectious complications in lymphoproliferative disorders. In patients with non-Hodgkin 
lymphomas infections originate from both the underlying disease and treatment of lymphoma. 
Infections are influenced by several factors, such as impaired cell-mediated and humoral 
immunity, hypogammaglobulinaemia, insufficient neutrophil function and complement 
activity, but the most important predisposing factor is neutropenia. During the initial phase of 
profound neutropenia, the dominating pathogens are bacteria, mainly Gram-positive cocci 
(Staphylococcus sp., Streptococcus sp. and Enterococcus sp.), are twice as likely as Gram-
negative bacteria. The defect in humoral immunity owing to the lack of normal B-
lymphocytes is associated with the inadequate production of IgM, IgG and IgA 
immunoglobulins, and due to this, opsonisation and phagocytic function are impaired. 
Because of these problems, encapsulated organisms (Streptococcus pneumoniae, 
Haemophilus influenzae and Neisseria meningitidis) may cause severe occasionally fatal 
infections in patients with a low level of immunoglobulins (see Table 1). Cell-mediated 
immune-deficiency often exists in malignant lymphoproliferative disorders, and in those 
patients treated with nucleoside analogues or monoclonal antibodies [82]. For these patients, 
the incidence of infection casued by intracellular pathogens such as Salmonella sp., 
Mycobacterium sp. and viral infections is also higher (see Table 1). The spectrum of 
infections and pathogens in lymphoproliferative disorders has been influenced by the 
introduction of new therapeutic drugs and monoclonal antibodies. Following the classic 
chemotherapeutic treatments, such as alkylating-containing regimens, infections are mainly 
caused by bacteria (such as S. pneumoniae, H. influenzae, Staphylococcus aureus, 
Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae) (see Table 1). The 
introduction of purine analogues in the treatment of lymphoproliferative malignancies 
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(especially in chronic lymphocytic leukemia (CLL)) has resulted in a change of 
microorganisms in general [84]. Due to the persistent immunosuppressive state, opportunistic 
infections caused by Nocardia sp., Mycobacterium sp., systemic fungi and herpesviruses are 
frequently detected [60, 61, 4]. 
 
Table 1. Summary of the most common pathogens in patients with malignant lymphomas 
(adapted from Rolston KV)[82]  
Bacterial 
pathogens 
Fungal pathogens Viral pathogens Parasites/Warm 
Streptococcus 
pneumoniae 
Aspergillus sp. HSV-1/2 Toxoplasma 
gondii 
Haemophilus 
influenzae 
Zygomycetes sp. CMV Strongyloides 
stercoralis 
Neisseria 
meningitidis 
Fusarium sp. EBV i 
Nocardia sp. Pneumocystis 
jiroveci 
VZV  
Salmonella sp. Cryptococcus 
neoformans 
HHV-6  
Listeria 
monocytogenes 
Candida sp.   
Campylobacter sp. Histoplasma 
capsulatum 
Scedosporium sp. 
  
Legionella sp.    
Capnocytophaga sp.    
Mycobacterium sp.    
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With the introduction of SCT and novel agents (bortezomib, thalidomide, and lenalidomide) 
in the treatment of multiple myeloma (MM) in the past few decades, the survival of patients 
with multiple myeloma has improved [67, 14]. In parallel with higher survival rates, it has 
brought about complications of the disease, such as infections. In spite of this, the infectious 
complications have induced a significant morbidity and mortality in this patient group [87]. 
According to Augustson et al., a higher rate of early death (45%) was observed in this patient 
group because of infection within 6 months from the time of diagnosis [9]. A higher risk of 
infection may be a result of antineoplastic therapy of MM, and impaired humoral and cellular 
immunity. B-cell dysfunction may result in hypogammaglobulinemia, and a decreased 
number and function of natural killer (NK) and CD8+ T-cells may lead to the development of 
infections [83]. In Sweden, a large population-based study was carried out between 1988 and 
2004, and was followed up in 2007. Over 9253 patients with MM, and 4931 matched controls 
were recruited to estimate the risk of infections. They found that infection-related deaths were 
significantly higher in MM patients than in the control group, and the risk of infection 
increased mainly in the first six months from the time of diagnosis [14, 9]. Offidani and co-
workers examined the infection rate in patients with a thalidomide-containing regimen, and 
they found that the infection rate was 42%, and that 19% of these infections were severe [88].  
Because of persistent immunosuppression in patients, bacterial infections are among the 
major complications of haematopoietic stem cell transplant (HSCT) patients. High dose 
chemotherapy supported by autologous stem cell transplantation is a widely used method for 
malignant haematological diseases - mostly multiple myeloma and lymphomas [51]. BSIs, 
gastrointestinal infections and pneumonia are the most frequent bacterial infections in this 
patient group. The incidence of BSIs after HSCT varied between centers, but the BSI rate is 
5-10% for autologous HSCT recipients, while in an allogeneic setting, 20-30% of recipients 
had BSI [10]. During the pre-engraftment neutropenia, the incidence of BSIs is higher and the 
rate is influenced by the degree of oral and enteric mucositis and the use of a central venous 
catheter. During the non-neutropenic phase, BSIs are frequently detected in the case of Graft-
versus-Host-Disease, hypoglobulinaemia, and the presence of central venous lines. 
Staphylococci, mostly coagulase-negative staphylococci, are the most frequent cause of BSI 
after HSCT, while the second most common pathogens are the members of 
Enterobacteriaceae family, mainly E. coli (Eschericia coli); and the third most frequent 
bacteria are enterococci. Unfortunately, in the case of these pathogens, we are confronted by 
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increasing resistance rates; namely, the methicillin-resistance of S. aureus (Staphylococcus 
aureus/MRSA), the production of ESBLs (extended-spectrum beta-lactamases) among Gram-
negative bacteria and vancomycin resistant enterococci (VRE) are becoming more frequent 
after HSCT [10]. Retrospective studies showed that the rate of pneumonia in HSCT recipients 
is 15-25%; bacterial pneumonia (44%) are more frequent than fungal- (29%) and viral- (19%) 
pneumonia [45, 48]. The most frequent bacterial pathogens are E. coli, and Pseudomonas 
aeruginosa (P. aeruginosa), while because of the use of immunisation and prophylaxis S. 
pneumoniae are responsible for 5% of pneumonias [10]. In the case of gastrointestinal 
infections, CDI (Clostridium difficile infection) is the most frequent cause of diarrhoea after 
HSCT. During the first year after transplant, the rate of CDI is between 5.7% and 24.7%, and 
CDI is more frequently detected in the early phase of HSCT [2, 21].  
1.1.2. Viral infections among haematological patients after chemo-immunotherapy and 
patients who had undergone autologous stem cell transplantation 
Viral infections are an important cause of morbidity and mortality of patients with malignant 
haematological diseases; however the exact incidence mainly in the case of non-transplant 
patients is not yet well described. The main causes of this are the following: the 
microbiological diagnosis of a viral infection is difficult mainly because of the 
immunosuppression, serology is usually not adequate method to set up the diagnosis, while 
molecular techniques are the most sensitive methods. Because of the high cost, these methods, 
mainly validated, quantitative PCRs (polymerase chain reactions) are not widely available in 
certain countries. The most common viral infections in this patient group are CMV, EBV, 
HSV-1/2, and VZV; among the respiratory viruses, RSV, the influenza virus and 
parainfluenza virus infections are the best characterised. Moreover, the role of adenoviruses, 
metapneumovirus, BK virus and HHV-6 in patients with haematologic disorders is newly 
recognised [111]. 
Over 130 herpesviruses of the Herpesviridae family are known and have been isolated from 
several animals. Herpesvirales ordo contains three families, these being Herpesviridae, 
Alloherepesviridae and Malacoherpesviridae. The Herpesviridae family also contains three 
subfamilies, Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. Up until now, 
eight species of herpesviruses are known to infect human individuals, these being human 
herpesvirus 1 (HHV-1) or herpes simplex 1 (HSV-1), human herpesvirus 2 (HHV-2) or 
herpes simplex 2 (HSV-2), human herpesvirus 3 (HHV-3) or varicella-zoster virus (VZV), 
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human herpesvirus 4 (HHV-4) or Epstein-Barr virus (EBV), human herpesvirus 5 (HHV-5) or 
cytomegalovirus (CMV), human herpesvirus 6 (HHV-6A and HHV-6B), human herpesvirus 7 
(HHV-7) and human herpesvirus 8 or Kaposi sarcoma-associated herpesvirus (HHV-8 or 
KSHV) (see Fig. 2). Besides these, Macacine herpesvirus 1 can cause an infection in human 
individuals [105]. 
 
Figure 2. Taxonomy of herpesviruses  
(source: https://www.antiviralintelistrat.com/1/Viral_Taxonomy) 
 
The viral genome of these herpesviruses is double-stranded DNA (dsDNA) coated with 
icosahedral nucleocapsid. This nucleocapsid is covered by a pleomorph envelope. Between 
the envelope and nucleocapsid, tegument (matrix) can be observed (see Fig. 3.). On the basis 
of the microscopic morphology of herpesviruses, various species of herpesviruses could not 
be differentiated. Members of Alphaherpesvirinae including HSV-1, HSV-2, and VZV have a 
short life cycle and these viruses can spread rapidly and cause mainly mucocutaneous 
infection, while for Betaherpesvirinae (CMV, HHV-6 and HHV-7) the life cycle is slow; the 
infection is spread via saliva, genital secretes, blood or stem cell products, and these viruses 
may be latent in mononuclear cells. Gammaherpesvirinae including EBV and HHV-8 can 
establish latency in lymphoid cells and may cause a lytic infection in epithelial and fibroblast 
cells [79]. During infection, herpesviruses may enter the cells by endocytosis, the viral 
envelope fuses with the membrane of endocytotic vesicle and the viral nucleocapsid is finally 
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transported from the cytoplasm to the nucleus of the host cell. In the nucleus, the linear viral 
DNA will be circularised and DNA replication can begin. Viral gene expression is 
characteristic in herpesviruses and this process starts with the expression of immediate-early 
genes that code proteins regulating further gene expression. This is followed by the 
expression of early viral proteins that are necessary for DNA replication and protein 
phosphorylation; lastly late proteins are expressed, several of these being major structural 
proteins [79].   
 
 
Figure 3. Structure of herpesviruses (source: 
http://viralzone.expasy.org/all_by_species/185.html) 
Herpesviruses except VZV (airborne transmission) is mostly spread by direct contact, such as 
by infected saliva (CMV, EBV, HSV, and HHV-6). Sexual transmission (HSV, CMV, and 
HHV-8) and intrauterine infection (CMV, HSV, and VZV) can also occur. However, the 
majority of HSV infected infants acquire HSV infection at the time of delivery. CMV and 
EBV are spread via blood transfusion, while CMV, EBV and HHV-8 are also spread by organ 
transplantation [79].  Clinical syndromes caused by herpesviruses are similar, such as skin 
lesions, encephalitis, retinitis, hepatitis, mononucleosis and mononucleosis-like syndromes, 
Hence there is a need for clinical microbiology to establish a diagnosis [79].  
The biology of human cytomegalovirus (CMV) and infections associated with this virus. 
CMV, formally designated human herpesvirus 5 (HHV-5), is a member of the 
Betaherpesvirinae subfamily of the Herpesviridae family. This is the largest member of 
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human herpesviruses that was first isolated from the salivary gland, while a description of the 
CMV disease was first reported in 1965 [79]. The structure of this virus is similar to that of 
HSV and VZV. The viral genome is linear dsDNA, which contains 164 non-overlapping open 
reading frames and it is completely sequenced. CMV DNA is located in a nucleoprotein core 
that is surrounded by a matrix protein and pp65 antigen. The CMV genome has a single 
replication origin and contains a DNA polymerase gene (UL54). Another important gene is 
UL97, which encodes phosphotransferase enzyme. This enzyme can phosphorylate 
ganciclovir to ganciclovir monophosphate, this step being essential for ganciclovir to inhibit 
viral replication. CMV has also several genes that can downregulate the host’s immune 
response. CMV enters the host cell via endocytosis, and like other herpesviruses the viral core 
is transported from the cytoplasm to the nucleus where after the synthesis of DNA 
polymerase, viral replication occurs. The consequence of viral replication is the development 
of nuclear viral inclusions [79]. CMV infection as an endemic, seasonal variation could not be 
detected (i.e. it occurs all year round). After infection the virus remains dormant in 
monocytic/macrophage cells. In humans, the virus can infect various cell types including 
epithelial-, endothelial-, neuronal-, smoth muscle-cells and fibroblast. Seropositivity rate 
changes lie between 40% and 90%, and they exceed 90% in the adult population. CMV 
infection is often asymptomatic in a healthy individual, but sometimes a mononucleosis-like 
syndrome may occur in young adults. With cytomegalovirus mononucleosis, fever, 
lymphadenopathy and relative lymphocytosis like EBV mononucleosis may be observed, but 
the heterophil agglutinin test is negative, and a sore throat with enlarged tonsils is not 
characteristic; at the same time only low-level liver function abnormalities can be seen. In an 
immunocompromised host, CMV-related disease may involve almost any organ, but the most 
common are the lung and gastrointestinal tract [5, 23,111]. Interstitial pneumonia is one of the 
most frequent complications of CMV infection in immunocompromised hosts - mainly in 
haematopoetic stem cell transplants -, and with this complication is associated a high 
mortality even with aggressive antiviral therapy. Hepatitis and granulomatous hepatitis are 
usually associated with CMV mononucleosis and these may resolve fully. Another 
complication of CMV infection mainly in immunocompromised patients is 
meningoencephalitis with motor and sensory weakness. Myocarditis, thrombocytopenia and 
haemolytic anaemia are rare complications of CMV mononucleosis in otherwise healthy 
children or adults. In immunocompromised patients, the gastrointestinal manifestation of 
CMV infection may be present as ulcers in the oesophagus and colitis with severe explosive 
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watery diarrhoea. However, the incidence of CMV infection and disease is less clearly 
defined among patients with malignant hematological disorders [25, 52, 53]. Various studies 
have shown that the rate of severe CMV disease is higher among patients with cell-mediated 
immune-deficiencies following a stem cell and solid-organ transplant. However, CMV 
reactivation and infection are unusual infectious complications in patients with hematological 
diseases treated with conventional chemotherapy and these patients did not have stem cell 
transplantation [7, 86]. In stem cell transplant recipients, the rate of CMV reactivation is 
about 30-70% [6, 16]. In particular, this rate is much lower in autologous stem cell transplant 
recipients or in patients treated with high-dose chemotherapy than in an allogeneic setting. 
The laboratory diagnosis of CMV infection is based on the culture of the virus taken from 
various body fluids or the detection of viral antigen or viral DNA or CMV specific antibodies. 
The first laboratory test to establish the diagnosis of CMV infection mainly in infants with 
cytomegalic inclusion disease involved the detection of large nuclear inclusion-bearing cells 
in the urine. Another diagnostic method is the culture of viruses in human fibroblast cell line 
(MRC-5 cells), but as this is quite a labour-intensive and time-consuming method, these 
methods are not frequently used nowadays. The direct detection of antigens such as CMV 
matrix protein pp65 in neutrophils using monoclonal antibody is frequently used in patients 
with immunosuppression. However molecular methods like real-time quantitative PCR have a 
higher sensitivity, therefore these techniques are more reliable diagnostic tools in 
immunocompromised patients. With the use of molecular methods, it is possible to commence 
antiviral treatment in order to prevent the development of CMV end-organ disease, so the use 
of the molecular method provides the basis of preemptive therapy. In immunocompetent 
hosts, the majority of laboratories use ELISA (an enzyme-linked immunosorbent assay) for 
the detection of cytomegalovirus specific IgM and IgG, but the value of IgM detection is 
questionable because IgM may be present in the case of primary infection, reinfection and 
reactivation as well. At the same time after acute infection, IgM may persist for several 
months and with other herpesvirus infections we may get a false positive IgM result. Thus 
IgG seroconversion is indicative of a primary CMV infection, while in the case of the 
presence of the cytomegalovirus specific IgM, performing the IgG avidity test is a useful 
alternative to establish the diagnosis of acute cytomegalovirus infection. 
In the case of antiviral therapy we need to distinguish between antiviral prophylaxis (the 
routine administration of antiviral drug for a fixed period at the patient’s risk to prevent CMV 
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reactivation) and preemptive therapy (based on the detection of viral reactivation by the 
molecular method, a pp65 antigenemia assay or culture; therefore the early introduction of 
antiviral therapy could prevent a progression to the CMV disease). Three antiviral drugs 
[ganciclovir (GCV), foscarnet, cidofovir (CDV)] have been shown to be efficacious and have 
been approved in the treatment of CMV infection. The mechanism of action of these drugs are 
an inhibition of the viral DNA polymerase. Ganciclovir is a guanosine nucleoside analogue, 
and this was the first effective antiviral drug against CMV disease in human individuals [38]. 
The UL97 gene of CMV produces phosphotransferase, which converts GCV to GCV 
monophosphate, and it then is phosphorylated to GCV triphosphate. The triphosphorylated 
form of ganciclovir specifically inhibits the viral DNA polymerase. CMV resistance to GCV 
is developed by point mutation of the UL97 gene, and the another type of GCV resistance is a 
consequence of mutation in the viral DNA polymerase gene [74, 75]. Valganciclovir (VGC) 
is a prodrug of the GCV with a much higher bioavailability. Its oral form is equivalent to 
intravenous GCV. Foscarnet is a pyrophosphate analogue, and acts by direct binding to the 
viral DNA polymerase (CMV and other herpesviruses). Foscarnet is a treatment option for 
GCV-resistant CMV infection. It is administered intravenously, and it has a metabolic and 
nephrotoxic adverse reaction, such as renal failure, hypocalcaemia, hypomagnesaemia, 
hypophosphataemia [42], thus the close monitoring of serum creatinin and above-mentioned 
electrolytes levels, and supplementation of it are essential during therapy. Foscarnet resistant 
strains of CMV have been published because of the viral DNA polymerase gene mutation [27, 
28].  Cidofovir (CDV) is a nucleotide analogue of cytosine with potent anti-CMV activity. 
The phosphorylation step is not necessary using a viral enzyme. CDV was found to be 
effective in the treatment of CMV infection in patients undergoing allogeneic stem cell 
transplantation. In a retrospective study, Ljungman et al. analysed 82 allogeneic stem cell 
transplant patients, and data were gathered concerning the toxicity and efficacy of CDV. The 
dose of CDV was 1 to 5 mg/kg once a week, and followed by maintenance therapy every 
second week. Twenty patients with CMV disease (16 with pneumonia) were treated with 
CDV, and 50% of them responded to CDV therapy (9 out of the 16 patients had pneumonia).  
CDV is also effective as a second-line therapy in relapsing cases after GCV or foscarnet 
treatment [70]. One of the most important side effects is proximal renal tubular damage.  
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Biology of human herpesvirus 6 (HHV-6) and infections associated with this virus. Human 
herpesvirus 6 (HHV-6) is a member of Herpesviridae family and it is grouped into 
roseoloviruses with Human herpesvirus 7 (HHV-7). This virus was first isolated from patients 
with AIDS and lymphoproliferative disease in 1986 [58, 100], and it is genetically related to 
CMV [1]. There are two variants of HHV-6, namely HHV-6A and HHV-6B; on the basis of 
sequence analysis of their genomes, the differences between these two types are 5% [120]. 
The seroprevalence is above 95% in adults, but current serologic tests cannot distinguish 
between HHV-6A and HHV-6B infections, hence precise data about their seroprevalence are 
not available [19]. HHV-6 have a wide cell tropism; and in vitro studies have confirmed the 
presence of this virus in the brain, tonsils, salivary glands, kidneys, liver, lymph nodes, 
endothelial cells, and monocytes/macrophages, but the virus may infect preferably activated 
CD4+ T lymphocytes, and the infected cells display characteristic features such as 
cytomegalia, and ballooning. As regards HHV-6A, CD46 (a regulator of complement 
activation) is the major receptor for cell entry. This receptor can be found on all nucleated 
cells, while for HHV-6B, CD134, a member of tumour necrosis factor (TNF) receptor 
superfamily serves as a receptor for entry, and this receptor can be detected only on activated 
T lymphocytes [1]. Latency in monocytic/macrophage and bone marrow progenitor cells has 
also been confirmed; hence the virus can establish a lifelong infection characteristic of other 
herpesviruses [120]. Genomic HHV-6 DNA may be present as covalently integrated DNA in 
the subtelomeric region of the host chromosome [1]. A specific region of the viral genome 
including terminal direct repeats is responsible for the chromosomal integration [1].  
The pathogenic role of this virus in exanthema subitum (roseola infantum) was first described 
in 1988 by Yamanishi [116] et al. [24]. The majority of HHV-6 infections, including primary 
infection, reactivation and reinfection are asymptomatic [1]. HHV-6 infection is mostly 
acquired early in life - in general between 6 months and 2 years of age. Primary infection 
mostly manifests itself as undifferentiated febrile illness within the first 2 years of life. HHV-
6A may cause a primary infection in childhood, but sometimes it may be asymptomatic, and 
the etiologic role in infections is less well known. HHV-6B is known to be the causative agent 
of roseola infantum or exanthem subitum [19]. The typical symptom in exanthema subitum is 
a high fever for 3-4 days, and after this fever, measles-like or rubella-like macular or papular 
rashes appear [120]. Other symptoms, such as diarrhoea, respiratory symptoms, convulsions, 
cervical lymphadenomegaly, and anterior fontanelle bulging during HHV-6 infection may be 
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also observed, and with these unspecific symptoms HHV-6 infection is frequently 
underdiagnosed [120]. Because of the latency, HHV-6 can be reactivated in the case of 
immunosuppressive circumstances, such as following intensive chemotherapeutic treatment, 
solid organ, bone marrow and stem cell transplantations. The first case of fatal encephalitis 
following bone-marrow transplantation was described by Drobyski et al. in 1994 [41]. The 
risk of HHV-6 reactivation is associated with allogeneic (mainly cord blood) transplantation 
and rarely with autologous stem cell transplantation. In this case, the symptoms range from 
asymptomatic infection to severe manifestations (encephalitis, pneumonitis, hepatitis and 
myelosuppression), prolonged haematopoietic recovery and graft rejection. Encephalitis is 
one of the most frequent and life-threatening clinical complications of reactivation [19]. 
Reactivation has been documented by molecular techniques in 40-60% from peripheral blood 
and in 1-2% from cerebrospinal fluid associated with neurological signs [56, 112,117]. In 
addition to this, a diagnosis may be possible based on the detection of viral antigens or 
antibodies from various clinical specimens; however, the interpretation of results is 
complicated because of the high seroprevalence, immunosuppression and latent form of the 
virus [19]. On the basis of these, various aims have been decided in the virological diagnosis 
of HHV-6 infection, namely the detection of HHV-6A and HHV-6B infection, the 
determination of the status of this infection (latent or active or ciHHV-6 related), the 
determination of viral load, and the question of treating this infection [1]. Various laboratory 
methods are available for the detection of HHV-6 infections, these being serological assays 
and molecular methods. Serological assays (indirect immunofluorescence assays, ELISA and 
immunoblot) are relatively cheap and easy to carry out, and a large number of sera can be 
investigated simultaneously, but these assays have several limitations, two being that the 
presence of IgM and the rapid increase in the level of IgG are not specific for acute HHV-6 
infection. At the same time other herpesvirus infections may cause false positive results; 
serologic findings may be atypical with immunocompromised patients and chromosomally 
integrated HHV-6 [1]. Because of various drawbacks of serological assays, they are useful in 
the case of the diagnosis of primary infection, the identification of HHV-6 in naïve subjects 
and seroprevalence studies [1].  Among direct methods, viral isolation is a reference method. 
However this method has a poor sensitivity and preparing the viral culture is time-consuming 
and quite expensive; hence this method is not recommended for diagnostic use. 
Immunohistochemistry techniques also have low sensitivities, so the use of these methods is 
limited. These days, molecular methods are widely available for diagnostic purposes like the 
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detection of HHV-6A and HHV-6B and the determination of viral load from various types of 
samples including plasma, cerebrospinal fluid and any other body fluids [1].  
 
2. AIMS OF THE STUDY 
The changing epidemiological patterns of infections in patients who suffer from 
hematological malignancy are characterised not only by the increasing incidence of some 
opportunistic pathogens, but also by the wide emergence of resistance to antimicrobials, 
especially in bacteria. In the practice of antimicrobial prophylaxis, it is crucial to continuously 
keep abreast of new epidemiological data in order to monitor the emerging antimicrobial 
resistances and define tailored prevention strategies. Based on findings of various 
international surveys and the lack of local data on the epidemiology of bloodstream and viral 
infections in patients with haematologic malignancy, the aims of this study were to establish 
the epidemiology of these diseases in patients at the Department of Haematology, University 
of Szeged in Hungary. In other words, we sought 
1. To evaluate the occurrence of bacterial species causing bloodstream infections in 
febrile neutropenic episodes between 2005 and 2008. 
2. To characterise bloodstream infections caused by “unusual” pathogens including 
Fusobacterium spp., Nocardia spp., and Achromobacter spp. 
3. To present the results of CMV monitoring in patients with haematological diseases, 
and following autologous stem cell transplantation. 
4. To determine the occurrence of HHV-6 infection in autologous stem cell transplant 
recipients. 
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3. MATERIALS AND METHODS 
3.1. COMMONLY USED DEFINITIONS 
Febrile neutropenia. Febrile neutropaenia was defined if a single oral temperature was 
measured higher than 38.3 °C, or the temperature was 38.0 °C or higher for 1 hour. 
Neutropenia is defined as when the absolute neutrophil count (ANC) is less than 0.5xG/L or 
less than 1.0xG/L and it rapidly declines below 0.5xG/L [55]. 
Classification of febrile episodes. Three distinct groups of febrile episodes were distinguished 
in neutropenic patients. Microbiologically documented infection (MDI) means a positive 
culture result can be confirmed from different sites (blood or other specimens). Clinically 
documented infection means features of infections are diagnosed clinically or by radiographic 
examinations without positive microbiologic samples. Fever of unknown origin (FUO): 
means there is no evidence of positive microbiological results or no clinical/radiographic 
signs of infection could be detected [64, 82]. 
Polymicrobial bloodstream infection. BSI infection is defined as polymicrobial if more than 
one species of bacteria grew from BC (blood culture) on the same day. In a neutropenic 
setting, the rate of polymicrobial origin is roughly 15-25% of BSIs [64, 96]. The typical organ 
involvement of polymicrobial infections is predominantly the enterocolitis, perirectal and skin 
infection [96].  
Bloodstream infections caused by rarely isolated bacteria, and the occurrence of infections 
on unusual localisation. About 10-15% of infectious complications of neutropenic patients 
appear in unusual localisation including central nervous system involvement (meningitis and 
brain abscess), septic arthritis, and septic involvement of the liver, spleen and kidneys caused 
by rarely isolated bacteria [43, 82, 92, 95]. 
3.2. BLOODSTREAM INFECTIONS IN PATIENTS WITH HAEMATOLOGIC 
MALIGNANCY 
3.2.1. Patients 
Between 2005 and 2008, 469 patients with febrile neutropenia (230 females and 239 males, 
median age 60 years) were examined at our department. The data collected from patient 
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documentation included the demographics of patients, diagnosis, febrile episodes, source of 
fever and source of infection, neutrophil count, and clinical significance of the isolated 
organism. Infectious complications were categorised into three groups, namely 1 - FUO, 2 - 
MDI, 3 - clinically documented infection. Definitions of febrile neutropenia, neutropenia, and 
polymicrobial BSI were used (see above). A single positive BC was considered significant if 
the isolated strain was a clinically relevant cause of the infection. Common skin contaminants 
(CNS (coagulase-negative staphylococci) and propionibacteria) were considered significant 
only if they were found in two consecutive BC samples or if there were concurrent skin, soft 
tissue or catheter–related infections. Microbiological results were retrieved from the Clinical 
Microbiology Laboratory information system. A medical database of patients was used to 
collect information on the haematologic diseases, presence of a febrile neutropenic episode, 
the duration of neutropenia, and the source of the infection. 
3.2.2. Analysis of blood cultures 
BCs were collected at the onset of a fever. In patients with central venous catheters, BCs were 
taken simultaneously from both central and peripheral veins. For the collection of blood 
culture, blood culture systems (BD Bactec, Beckton Dickinson, USA) including aerobic, 
anaerobic bottles and bottles for fungi were used. After the collection of blood, the bottles 
were immediately placed in an incubator, where they were incubated for 5-14 days, depending 
on the type of the putative pathogens. In the case of a positive signal produced by the 
instrument based on bacterial or fungal growth, microscopic examinations (Gram stained 
preparations) and culture were performed. For an aerobic culture, Columbia blood agar 
supplemented with 5% sheep blood (bioMérieux, Marcy l’Etoile, France), chocolate agar 
supplemented with PolyViteX (bioMérieux, Marcy L’Etoile, France), eosin-methylenblue 
(Lab M, UK) and Sabouraud Chloramphenicol (Bio-Rad, France) agars was inoculated, while 
for an anaerobic culture, Schaedler agar supplemented with 5% sheep blood (bioMérieux, 
Marcy l’Etoile, France) was inoculated. Plates were incubated at 37 °C for 24 hours in a 5% 
CO2 incubator or 37 °C for 24 hours at one atmosphere or at 37 °C for 48 hours in an 
anaerobic cabinet (Concept 400; Ruskinn Technology Ltd., Bridgend, UK) under a gas 
composition of 85% N2, 10% H2 and 5% CO2. From a pure culture, antibiotic susceptibility 
tests were performed on the basis of recommendations by the Clinical Laboratory Standard 
Institute [30-34].  
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3.2.3. Identification of bacteria and yeasts 
For the precise identification of bacteria and yeasts, traditional biochemical tests or automated 
identification systems, such as VITEK®2 ID (bioMérieux, France), API 20 A (BioMérieux, 
France), or RapIDTM ANA (bioMérieux, France) were applied on the basis of colony 
morphology, O2/CO2 requirement, and phase contrast microscopy findings. If the 
identification proved inconclusive using traditional or automated identification systems, the 
amplification of 16S rDNA was used. In short, nucleic acid from the colonies was purified 
using the QIAamp DNA mini kit (Qiagen) and the 16S rDNA was amplified using universal 
primers E8F (5’-AGAGTTTGATCCTGGCTCAG-3’) and E533R (5’-
TTACCGCGGCTGCTGGCA-3’). For amplification, the following cycling conditions were 
used: starting denaturation at 94ºC for 3 min; 35 cycles: denaturation at 94ºC for 15 s, 
annealing at 55.5ºC for 30 s, extension at 72ºC for 1 min; final extension at 72ºC for 10 min. 
The PCR product was purified using the High Pure PCR Cleanup Micro Kit (Roche, 
Germany) according to manufacturer’s instructions and the purified PCR product was 
sequenced. The sequences obtained were then compared with those stored in GenBank using 
BLAST alignment software (http://www.ncbi.nlm.nih.gov/blast). 
3.2.4. Antibiotic protocol 
At the onset of fever, after the collection of BC samples, empirical broad-spectrum antibiotic 
treatment was started (piperacillin-tazobactam, cefepime, and imipenem or meropenem). The 
antibiotic dosage was modified according to the patient’s renal function. Patients were 
examined once a day by their physician to detect any potential source of infection. After 48-
72 hours of observation, the patient’s condition was re-evaluated. Changes in empiric 
antibiotic therapy depended on BC results and clinical response. In afebrile and culture-
negative patients with a stable clinical state, empiric antibiotic treatment was continued until 
the ANC reached 0.5xG/L. Vancomycin was used in patients with central venous devices, 
persistent fever and hypotension. On days 4-5, in patients with a persistent fever that 
suggested a fungal infection on the basis of clinical signs and CT (computed tomography) 
scans, amphotericin-B was initiated. 
27 
 
3.3. MONITORING THE PRESENCE OF CMV IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
3.3.1. Patients and sample collection 
Between 2008 and 2014, 1238 plasma samples were collected from 271 patients with 
haematological diseases at our department (University of Szeged, Hungary). The clinical and 
demographic data of patients were gathered from the local medical computer-based database. 
The findings of serological investigations and CMV PCR were analysed retrospectively. 
Patients were divided into three groups according to the underlying disease (lymphoid and 
myeloid haematologic malignancies, and other haematologic diseases) and the first two 
categories were further divided into two subgroups: patients who underwent autologous stem- 
cell transplantation (ASCT) or not (non-ASCT). Patients in the ASCT group gave written 
informed consent for the transplant procedure. We also sought informed consent from patients 
with haematological diseases (non-ASCT) for the treatment according to the local policy of 
the hospital. The conditioning regimen for Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL) patients was BEAM (BiCNU®, etoposide, cytosine-arabinoside, melphalan 
supplemented with 375 mg/m2 of rituximab for CD20+ NHL patients); while for myeloma 
patients and with or without renal failure 200 mg/m2 or 140 mg/m2 of melphalan was used 
[26, 8, 11]. Out of 271 patients examined, 126 received unmanipulated autologous stem cells 
(2-7 x 106/kg, median: 4.94 x 106/kg, range: 2.73-7.15). All transplant patients were supported 
with filtered and irradiated blood products. Among patients, in the non-ASCT patient group 
undergoing purine-analogue-based chemotherapy, or anti-CD52 antibody or anti-thymocyte 
globulin, similarly filtered or leuko-depleted and irradiated red blood cell and platelet 
transfusions were used. Anti-infective prophylaxis for the ASCT patient group was 
fluconasole (100 mg once daily), and during the neutropenic phase, this was levofloxacin 
(500 mg once daily). Antiviral prophylaxis consisted of acyclovir (200 mg five times daily, 
and this was switched to 250 mg twice daily intravenously if the patient was unable to take 
solid oral dosage forms). The use of antiviral prophylactic agents was continued for 6 months 
post-ASCT. 
CMV specific antiviral therapy was initiated on the basis of at least two consecutive CMV 
DNA viral copy numbers if the copy number was >1000 copies/ml in one sample or if the 
copy number was <1000 copies/ml, but the copy number indicated that there was an 
increasing tendency in two consecutive specimens. 
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3.3.2. Determination of the CMV serologic status and monitoring for CMV DNA viral load 
Among non-ASCT patients with haematologic diseases, quantitative real-time CMV PCR 
from plasma was performed if febrile episodes of unknown origin without the presence of 
concomitant bacterial or fungal infections had arisen during antineoplastic treatment 
(especially the purine-analogue or monoclonal-antibody therapy associated with 
lymphopenia). In patients with ASCT, CMV PCR was carried out once a week until the 30th 
post-transplant day, and then non-regularly up to the 100th post-transplant day or during 
hospitalisation and occasionally during the stem cell harvesting period. For the determination 
of the CMV viral load, artus CMV RT PCR (Qiagen, Germany) was applied after nucleic acid 
isolation from plasma specimens was performed using the MagNa Pure Compact Nucleic 
Acid Isolation Kit I (Roche, Swiss). Nucleic acid isolation and quantitative real-time PCR 
were carried out according to the manufacturers’ recommendations. A serologic assay using 
ETI-CYTOK-M reverse Plus CMV IgM EIA (DiaSorin, Italy) and ETI-CYTOK-G Plus CMV IgG 
EIA (DiaSorin, Italy) was performed in the ASCT group before the stem cell harvesting 
procedure, while in the non-ASCT patients these tests were carried out occasionally. CMV 
symptomatic infection was defined if CMV DNAemia was detected in two consecutive 
specimens along with the clinical suspicion of reactivation. CMV end-organ disease was 
defined by the presence of symptoms consistent with CMV infection and the simultaneous 
presence of molecular, histopathological, clinical or imaging findings that suggested CMV 
infection [69, 72, 73]. As for the statistical methods applied, we used statistical software IBM 
SPSS Version 22. Among patient groups, we used the Mann-Whitney U-test to compare the 
baseline characteristics. The age was compared across CMV PCR positive and CMV PCR 
negative groups via the Mann-Whitney U-test. The independence of CMV PCR groups and 
sex, CMV PCR groups and the initial diagnosis was tested by the chi-square test for 
independence. Here, a p-value of <0.05 was deemed statistically significant. 
3.4. MONITORING THE PRESENCE OF HHV-6 IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
3.4.1. Patients 
Between 2010 and 2012, 35 consecutive patients that had undergone autologous peripheral 
stem cell transplantation were observed at our institution (namely, 19 females and 16 males 
with a median age of 60 years; range 22-71 years). The underlying diseases were multiple 
myeloma, Hodgkin lymphoma and non-Hodgkin lymphoma in 29, 2 and 4 cases, respectively. 
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One hundred and twenty-one anticoagulated (EDTA) blood and 2 cerebrospinal fluid (CSF) 
samples taken from the 35 patients were collected, which meant that at least 2 blood samples 
were taken from each patient (in 7 cases, only 1 specimen). All patients received antiviral 
prophylaxis against the herpes simplex virus-1/2 and varicella-zoster virus (acyclovir 400 mg 
twice daily), antibacterial (levofloxacin 500 mg once a day) and antifungal drugs (fluconazole 
150 mg once a day) for the prevention of infection. Engraftment was defined if the neutrophil 
and platelet count was more than 0.5 and 20xG/L on two consecutive days without any 
support, respectively.  
3.4.2. Molecular detection of HHV-6 
Plasma specimens and, in the case of neurological manifestations, CFSs were tested for the 
presence of CMV, HSV-1/2, EBV DNA using real-time PCR (artus CMV LC PCR Kit; 
Qiagen, Hilden, Germany, artus HSV-1/2 LC PCR Kit; Qiagen and artus EBV LC PCR Kit; 
Qiagen). HHV-6 nested PCR was performed with the use of Dream Taq Green PCR Master 
mix (2x) (Thermo Scientific; Waltham, MA, USA) containing a 2x DreamTaq Green buffer, 
0.4 mM dNTP, 4 mM MgCl2. The primers were derived from the immediate early gene locus 
of two variants of the HHV-6 strain (U1102) (115). Ten microliters of 1x DreamTaq Green 
PCR Master mix, 0.4 µl of 25 mM MgCl2 , 0.3 µl of 25 pmol HHV6-F out primer(5’-TTC 
TCC AGA TGT GCC AGG GAA ATC C-3’), 0.3 µl of 25 pmol HHV6-R out primer (5’- 
CAT CAT TGT TAT CGC TTT CAC TCT C-3’), 4 µl of H2O, and 5 µl of a purified DNA 
template were used for PCR. For the next PCR, 10 µl of 1x Dream Taq Green PCR Master 
mix, 0.4 µl of 25 mM MgCl2 , 0.3 µl of 25 pmol HHV6-F in primer (5’- AGT GAC AGA 
TCT GGG CGG GCC CTA ATA ACT T-3’), 0.3 µl of 25 pmol HHV6-R in primer (5’- AGG 
TGC TGA GTG ATC AGT TTC ATA ACC AAA-3’), 4 µl of H2O and 5 µl template (from 
the samples amplified in the course of the previous PCR) were prepared. The amplified PCR 
product was detected using gel electrophoresis and two variants of HHV-6 were identified on 
the basis of the size of the amplified products (variant A gave 195 bp, while variant B gave 
423 bp of PCR products). 
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4. RESULTS 
4.1. BLOODSTREAM INFECTIONS IN PATIENTS WITH HAEMATOLOGIC 
MALIGNANCY 
Between 2005 and 2008, 1361 patients were hospitalised in the haematology 
department because of various haematological diseases, and the average number of cases/year 
was 340. Alltogether 812 febrile episodes were recorded in 469 (34.5%) patients and blood 
was collected for microbiological culture. Of the 469 patients, 128 (27.3%) had acute myeloid 
leukaemia, 85 (18.1%) non-Hodgkin’s lymphoma, 66 (14.1%) multiple myeloma, 64 (13.6%) 
chronic lymphocytic leukaemia, 41 (8.7%) acute lymphoblastic leukaemia and 85 (18.1%) 
others (Hodgkin’s lymphoma, myelodysplastic syndrome, chronic myeloprolipherative 
disorders, etc.). Altogether 3714 blood culture bottles, 7.9 bottles/patient (ranging from 2-12) 
were sent to the laboratory. In 126 (27%) cases of the 469 patients, only one pair of blood 
culture bottles was taken for an analysis of febrile episodes. Clinically documented infections 
were observed in 430 cases (52.95%) of 812 febrile episodes. The majority of them were 
localised to the lungs (39.5%). Colitis and skin and soft tissue infections were the second and 
third most common types of infection. 
Using a microbiological culture, 759 (20.4%) of 3714 blood culture bottles gave positive 
signals. From the majority of positive blood culture bottles (509 bottles (67.1%)), Gram-
positive bacteria were detected. Among Gram-positive bacteria, the most frequent isolates 
were coagulase-negative staphylococci (65%), S. aureus (10%), Enterococcus spp. (6.7%), P. 
acnes (5.7%), beta-hemolytic streptococci (3.1%), S. pneumoniae (2.8%), alfa-hemolytic 
streptococci (2.4%) Clostridium spp. (1.4%), and others (3%) (including Listeria 
monocytogenes, Nocardia farcinica, Gemella spp., Micrococcus spp., Brevibacterium spp., 
and Gram-positive non-identified bacteria) (See Table 2). 
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Table 2. Gram-positive bacteria isolated from blood cultures between 2005 and 2008. 
Isolated strain Number of isolated strains per annum Total  
N=509 (%)  2005 2006 2007 2008 
Coagulase-negative 
staphylococci 
94 73 86 78 331 (65) 
S. aureus 25 6 11 9 51 (10) 
Enterococcus spp. 6 9 5 14 34 (6.7) 
P. acnes 13 10 2 4 29 (5.7) 
Beta-hemolytic 
streptococci 
10 5 1 0 16 (3.1) 
S. pneumoniae 5 0 0 9 14 (2.8) 
Alfa-hemolytic 
streptococci 
0 7 1 4 12 (2.4) 
Clostridium spp. 2 4 0 1 7 (1.4) 
Others  
(L. monocytogenes, N. 
farcinica, Gemella spp., 
Micrococcus spp., 
Brevibacterium spp. etc.) 
4 6 2 3 15 (3) 
   
Gram-negative bacteria were isolated from 250 (32.9%) blood culture bottles. A high 
prevalence of E. coli (52%) could be detected in these specimens, while 14% of samples 
contained P. aeruginosa, 9.6% Klebsiella spp., 8% Enterobacter spp., 3.6% Citrobacter spp., 
Stenotrophomonas maltophilia 2%, Acinetobacter spp., and 1.6% Fusobacterium spp. (see 
Table 3). 
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Only 6 bottles proved positive for fungi during the period in question; in 2 cases, Candida 
albicans and also in 2 bottles, Candida tropicalis was detected, while 2 other bottles were 
positive for Cryptococcus spp. 
 
Table 3. Gram-negative bacteria isolated from blood culture bottles between 2005 and 2008. 
Isolated strain Number of isolated strains per annum Total  
N=250 (%)  2005 2006 2007 2008 
E. coli 22 38 41 29 130 (52) 
P. aeruginosa 6 6 10 13 35 (14) 
Klebsiella spp. 0 10 6 8 24 (9.6) 
Enterobacter spp. 7 3 0 1 20 (8) 
Citrobacter spp. 2 3 2 2 9 (3.6) 
S. maltophilia 0 0 2 3 5 (2) 
Acinetobacter spp. 0 1 1 2 4 (1.6) 
Fusobacterium spp. 0 2 2 0 4 (1.6) 
Others  
(H. influenzae, A. 
xylosoxidans, P. 
mirabilis, Salmonella 
spp., Neisseria spp., 
Gram-negative non-
identified rods etc.) 
5 4 5 5 19 (7.6) 
 
 
Among Gram-positive isolates, coagulase-negative staphylococci were identified in 331 
cases. These blood culture samples were collected from 161 febrile episodes of 149 patients. 
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In 50 febrile neutropenic episodes, CNS played a role as a causative agent of fever because of 
the coexistence of skin, soft tissue and central venous catheter-related infections. As for the 
remaining 111 cases, contamination might have been the source of CNS. Among rarely 
isolated pathogens, Listeria sp. was identified from one patient with AML due to a second 
relapse in 2006. The patient had clinically documented pneumonia, and was treated with 
ampicillin. Nocardia farcinica (N. farcinica) was also detected among rare pathogens in a 37-
year-old man diagnosed with large granular lymphocytic leukaemia. He underwent 6 cycles 
of combined chemotherapeutic treatment (Cytoxan, Vincristine, and Prednisone), and later 
had long-term steroid therapy due to Coombs positive haemolytic anaemia, and active 
haemolytic events. He was hospitalised due to several febrile episodes six months before 
present admission, but infectious agents could not be detected. Upon admission, the patient 
complained of general fatigue, fever, and vomiting. After hospital admission, headache and 
dizziness commenced. A neurological examination did not reveal any signs of meningitis. The 
serum laboratory results displayed a normal level of procalcitonin, liver and kidney function, 
elevated leukocyte count (34.2xG/L) with 80 % neutrophil cells, mild anaemia (haemoglobin 
level 113 g/L) and a normal platelet count (339xG/L). Three days later CT was performed 
because of central type paresis of facial and hypoglossal nerves. The CT scan revealed 
multiple lesions (6-13 mm in diameter) with perifocal edema. A stereotactic core biopsy from 
lesions could not be carried out because of a deterioration in the patient’s clinical status. 
Blood and urine samples for bacteriological culture were collected, and empiric antibiotic 
therapy (imipenem-cilastatin 500 mg every 6 hours) was started. Two blood culture bottles 
gave a positive signal after 52 h and 65 h of incubation; and in the Gram-stained preparations, 
Gram-positive branching filaments could be observed (Fig. 4A). After 24 h of incubation in 
air containing 5% CO2, small orange colonies had grown (Fig. 4B). Because of the 
unsuccessful identification of the isolated strains using a commercial kit (VITEK 2 GP ID 
card, BioMérieux), 16S rDNA sequencing was performed. On the basis of sequence analysis 
of the amplified PCR product, N. farcinica was identified. 
In 2006 and 2008, Burkholderia cepacea (B. cepacea) was identified in two patients. One of 
them was observed with AML, and did not receive any chemotherapeutic treatment. A blood 
culture sample was taken from a peripheral vein. Here, the patient was treated empirically 
with levofloxacin. The other patient suffered from relapsed Hodgkin lymphoma, and was 
treated according to the ESHAP chemotherapeutic regimen (which involves a combination of 
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high dose cytosine-arabinoside, methylprednisolone, cysplatin and etoposide) through the 
central venous line. Two pairs of blood culture samples were taken following a febrile 
episode from a catheter, and B. cepacea was grown from each sample. 
  
Figure 4. Microscopic results of blood culture of patients with N. farcinica sepsis (mag. 1 000x) (A) and colony 
morphology of N. farcinica on chocholate agar (B) (source: Terhes G.). 
Between 2005 and 2008, four cases of bacteremia caused by Fusobacterium nucleatum (F. 
nucleatum) were detected in patients with acute leukemia at our hospital. The first case was a 
51-year-old woman who was admitted to the Haematology Unit with acute myelomonocytic 
leukaemia; therefore cytosine arabinoside (2200 mg per day), mitoxantrone (15 mg per day) 
and etoposide (220 mg per day) therapies were given over five days. At the end of the 
chemotherapy, the patient developed a fever and oropharyngeal mucositis of World Health 
Organization (WHO) grade 3. The second case was a 71-year-old woman suffering from 
acute myeloid leukaemia, who was admitted to our department with a febrile episode, 
mucositis WHO grade 1 (soreness and erythema) and the possibility of perianal abscess. 
Laboratory investigations identified neutropenia and a high C-reactive protein level. Chest 
radiography revealed pulmonary infiltration in the upper right side of the lung. The third case 
was a 46-year-old man diagnosed with acute pre-B-cell lymphoblastic leukaemia. In his 
second remission, after consolidation therapy (high dose cytosine arabinoside and 
mitoxantrone), he developed a fever and neutropenia without mucositis despite the 
chemotherapeutic treatment. The fourth case was a 61-year-old woman with acute myeloid 
leukaemia, who had been admitted to the Haematology Unit because of a fever, cough and 
dyspnea. Her C-reactive protein level was elevated, and her absolute neutrophil count was 
0.2xG/L. She had severe oropharyngeal mucositis of WHO grade 3, while chest radiography 
A B 
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showed pulmonary infiltration on the left side of the lung. During the febrile period, at least 
one pair of blood samples was taken in aerobic and anaerobic bottles from all patients. In each 
case, only anaerobic bottles gave positive signals after 35-87 hours of incubation. On the basis 
of a microscopic examination, because of the characteristic morphology (see Fig. 5.), the 
possibility of bacteraemia caused by Fusobacterium sp. had arisen and empiric antibiotic 
therapy was started immediately. 
  
Figure 5. Characteristic microscopic findings concerning F. nucleatum bacteraemia (mag. 1000x) (A), and 
colony morphology of F. nucleatum on anaerobic blood agar (B) (source Terhes G.). 
Another rarely isolated pathogen from blood culture was Achromobacter xylosoxidans (A. 
xylosoxidans). A 41-year-old woman was admitted to our department because of acute 
promyelocytic leukaemia with disseminated intravascular coagulation. After the induction 
treatment she had febrile neutropenia. Empirical antibiotic therapy was started after taking a 
blood culture sample. Her clinical state was stable. A few days later, dyspnea and abdominal 
pain developed. Chest radiography showed pulmonary infiltration in the right side of the lung 
and interstitial pneumonia. A blood culture sample was taken again before changing 
antibiotics (carbapenem), and she was transferred to the Intensive Care Unit because of 
respiratory failure. She died of progressive pneumonia and acute respiratory distress 
syndrome a few hours later. During the febrile period, blood cultures were taken from the 
patient and a positive signal was generated in the case of 4 bottles. Phase contrast microscopic 
examination and acridine orange staining revealed long bacilli, which proved to be Gram-
negative in a Gram-stained smear. After 24 hours of incubation, greyish colonies could be 
observed on the surface of sheep blood agar and chocolate agar as well. The amplified partial 
16S rDNA PCR product of this strain was sequenced, and the generated nucleotide sequence 
A B 
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displayed 100% homology with A. xylosoxidans strain L2 2 by using the BLAST program 
(Fig. 6). 
  
Figure 6. Characteristic microscopic results concerning A. xylosoxidans bacteraemia (mag. 1 000x) (A), and 
colony morphology of A. xylosoxidans on blood agar (B) (source: G Terhes). 
 
4.2. MONITORING THE PRESENCE OF CMV IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
Between 2008 and 2014, 271 patients with haematological malignancies were tested for 
the presence of CMV DNA. In total, 1238 PCRs were carried out. The median age of the 
patients was 57 years (range 42-72 years) and 67% of the patients tested were above 50 years 
of age. The male to female ratio was 0.99; that is 135 men and 136 women. Below in Table 4, 
the patients’ characteristics are shown. A CMV serological assay was performed for 204 
patients. Here, 154 (75.5%) of the 204 patients had CMV specific IgG, while in the case of 
the remaining 50 (24.5%) patients the CMV IgG tests proved to be negative. 
 
 
 
 
 
 
 
 
A B 
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Table 4. Demographics and types of haematological malignancies of the patients examined. 
Variables   
All patients 271 
Mean age (yr) 57 (range 42-72) 
Sex   
    Men 135 
    Women 136 
Types of underlying diseases Number of patients (%) 
Number of patients 
underwent ASCT 
Lymphoid malignancies   
 Non-Hodgkin lymphoma 68 (25.1%) 37 
 Hodgkin lymphoma 23 (8.5%) 18 
 Multiple myeloma 80 (29.5%) 71 
 Chronic lymphocytic leukemia 39 (14.4%) 0 
 Acute lymphoblastic leukemia 14 (5.2%) 0 
Myeloid malignancies   
 Acute myeloid leukemia 23 (8.5%) 0 
 Myelodysplastic syndrome 3 (1.1%) 0 
Othersa 21 (7.7%) 0 
Total 271 (100%) 126 (46.5%) 
aSevere aplastic anaemia (n=5), autoimmune disease (n=6), common variable immunodeficient syndrome (n=2), 
fever of unknown origin (n=8) 
 
During the given period, 1238 plasma specimens were tested for the presence of CMV DNA 
using RT PCR. Out of the total plasma samples examined, 118 (9.5%) were positive, and 
these positive specimens were collected from 66 (24.4%) patients. 126 patients (46.5%) 
underwent autologous stem cell transplantation, while 145 (53.5%) of the patients examined 
with different malignant or non-malignant hematological diseases did not have stem cell 
transplantation (non-ASCT group). As regards the use of BEAM (55 patients), 13 (23.6%) 
specimens from patients proved to be positive for CMV DNA, while a higher CMV positivity 
rate (39.4%) was observed when patients were treated with melphalan (71 patients). 
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Twenty-four (16.6%) of 145 non-ASCT patients had CMV PCR positive specimens. Among 
the 24 CMV PCR positive patients, 6 of them had long-term steroid therapy as part of an ALL 
protocol and because of a severe haemolytic event. Before the CMV PCR positive results, 1 
T-ALL patient was treated with clofarabine because of a second relapse and 3 patients were 
treated with a GMALL protocol. Two severe aplastic anaemia (SAA) patients were treated 
with anti-thymocyte globulin + cyclosporine. Four of the 10 CLL patients were given 
alemtuzumab (an anti-CD52 antibody), 3 patients were treated with rituximab+fludarabine+ 
cyclophosphamide (R-FC), 2 patients were on rituximab+bendamustine and only 1 elderly 
woman was treated using chlorambucil monotherapy. R-FC and alemtuzumab were used for 
two relapsed PTCL patients (angioimmunoblastic subtype) before positive PCR. Two patients 
with common variable immunodeficiency syndrome (CVID) received immunoglobulin 
substitution regularly. The relapsed AML patient was treated with a fludarabine-containing 
regimen, while in the case of MM patients bortezomib-based therapy was used. Among non-
ASCT patients with positive CMV PCR results, 10 patients were asymptomatic, 14 had 
symptomatic reactivation, while 2 had CMV disease (1 ALL patient had colitis confirmed 
with colonoscopy and histology, while the other patient with common variable 
immunodeficient syndrome had CMV hepatitis). The most common clinical signs and 
symptoms of reactivation were fever (58%), diarrhoea (33%), pancytopenia (12.5%), and liver 
function abnormality (8.3%). Out of the 271 patients examined, 126 (46.5%) underwent 
autologous stem cell transplantation. High-dose chemotherapy with stem cell support was 
applied in patients with MM (n=71), aggressive NHL (n=37) and HL cases (n=18). Below in 
Table 5, the patient’s characteristics are listed.  
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Table 5. Characteristics of patients who underwent autologous stem cell support. 
Variables Number of patients (%) 
Non-Hodgkin lymphoma   37 (29.4) 
DLBCL 13 
                              FL    4 
                              PTCL    8 
                              MCL    12 
Hodgkin lymphoma    18 (14.3) 
Multiple myeloma    71 (56.3) 
Total 126 (100%) 
DLBCL-Diffuse Large B-Cell Lymphoma; FL-Follicular Lymphoma; PTCL-Peripheral T-Cell Lymphoma; 
MCL-Mantle Cell Lymphoma 
 
In the ASCT group, 42 (33.3%) patients had CMV PCR samples that proved positive. CMV 
reactivation was asymptomatic in 34 (81%) cases, in which spontaneous resolution could be 
observed, while 8 (19%) patients had symptomatic reactivation. All of these patients had a 
fever, 4 patients had cytopenia, prolonged engraftment, and only 1 patient had CMV 
pneumonia (and the post-mortem diagnosis was confirmed histologically). The majority of 
positive CMV PCR results (45.2%) were observed in the ASCT group between 20-40 days 
after transplantation, while 5 patients had a positive PCR result between 10-20 days after 
transplantation, and only 3 specimens proved to be positive 100 days after transplantation. 
The viral load in PCR positive specimens was under 1000 copies/ml in 87 (72%) cases. No 
significant differences could be observed between the CMV PCR positive and negative 
groups according to age, sex and initial diagnosis (p=0.987, p=0.411, p=0.416), respectively. 
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A total of 24 patients received antiviral therapy (intravenous ganciclovir 5 mg/kg twice daily 
or oral valganciclovir 900 mg daily) until resolution of the clinical signs and after two 
consecutive negative or decreasing CMV PCR results. 
 
4.3. MONITORING THE PRESENCE OF HHV-6 IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
Four out of 35 (11.4%) of patients tested using the PCR method post-transplant had 
HHV-6 positivity in the peripheral blood or CSF. Two patients had HL and two patients 
suffered from MM. The patients with MM were given a combination of thalidomide (Thal) 
and dexamethasone (Dex); in HL patients, a combination treatment of ABVD (Adriamycin, 
Bleomycin, Vinblastine and Dacarbazine) and DHAP (Dexamethasone, Cisplatin, Cytarabine) 
was applied. The HHV-6 variant A was detected only in MM patients, while the HHV-6 
variant B was amplified from HL. In the case of 1 MM patient with HHV-6 variant A, CMV 
DNA was also detected with a low copy number (273copies/ml) from the plasma specimen 
using real-time PCR. The patients’ characteristics are summarised in Table 6. Three of the 4 
patients did not show clinical signs of infection at the time of sample collection, while patient 
4 had limbic encephalitis. 
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Table 6. Characteristics of patients with HHV-6 PCR positive results. 
HL: Hodgkin Lymphoma; MM: multiple myeloma; M: male; F: female; CMV: cytomegalovirus; **: identified 
from cerebrospinal fluid and MRI findings; Thal: thalidomide; Dex: dexamethasone; ABVD: Adriamycin, 
Bleomycin, Vinblastine and Dacarbazine; DHAP: Dexamethasone, Cisplatin, Cytarabine Q3-4w; ICE: 
Ifosfamide, Carboplatin, Etoposide; BEAM: Carmustine (BiCNU), Etoposide, Arabinoside and Melphalan and 
HD Mel: high dose Melphalan. 
 
Patient 4, a 32- year-old man with stage II/A Hodgkin lymphoma, nodular sclerosis subtype, 
EBV-negative), was admitted to our haematology department in 2011. The patient had been 
treated with six cycles of chemotherapy according to the ABVD protocol that conferred 
complete remission (18). Four months later, the positron emission computer tomography 
(PET CT) showed an early relapse in his right supraclavicular and upper mediastinal lymph 
nodes, hence treatment with the DHAP regimen was started. After receiving a second course 
of DHAP, a peripheral blood stem cell harvest was performed (5.56x106/ body weight; CD34 
positive cells). The patient was conditioned according to the BEAM protocol (26) followed by 
P
a
ti
en
ts
 A
g
e 
in
 
y
ea
rs
 a
n
d
 s
ex
 
U
n
d
er
ly
in
g
 
d
is
ea
se
 
P
re
tr
a
n
sp
la
n
t 
tr
e
a
tm
en
t 
C
o
n
d
it
io
n
in
g
 
re
g
im
en
 
C
D
3
4
+
 1
0
6
/k
g
w
 
o
f 
ce
ll
s 
E
n
g
ra
ft
m
en
t 
o
f 
n
eu
tr
o
p
h
il
/ 
p
la
te
le
t 
(p
o
st
 
tr
a
n
sp
la
n
t 
d
a
y
s 
tr
a
tr
a
n
sp
la
n
t 
d
a
y
s)
 
T
y
p
e 
o
f 
H
H
V
-6
 
C
o
ex
is
te
n
ce
 o
f 
o
th
er
 v
ir
a
l 
D
N
A
em
ia
  
C
li
n
ic
a
l 
si
g
n
s 
o
f 
in
fe
ct
io
n
 
B
a
ct
er
ia
l/
fu
n
g
a
l 
in
fe
ct
io
n
s 
(1) 
19/M 
HL 
ABVD 
DHAP 
ICE 
BEAM 5.55 
8/12 B - - -/- 
(2) 
61/M 
MM 
Thal-
Dex 
HD 
Mel 
5.56 10/10 A - - -/- 
(3) 
56/F 
MM 
Thal-
Dex 
HD 
Mel 
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autologous stem cell infusion. On post-transplant day 17, the patient was referred to a 
neurologist because of confusion. Elevated liver enzymes and differences in the kidney 
enzyme levels were observed, while fever appeared and disappeared periodically. The first 
neurological examination did not reveal any focal neurological signs. The patient was vigil, 
disoriented in time and space but oriented in own data; however, he was psychomotorically 
slow. No signs of neck-stiffness and meningeal irritation could be observed. Cranial nerves 
without abnormalities, normal muscle tonus and strength and distally decreased vibration 
sensation in both legs were noted. Minimal symmetrical hyporeflexia in the Achilles and 
plantar deep tendon reflexes and insecurity with the Romberg test could be seen. Otherwise, 
tendon reflexes, coordination and cerebellar tests proved to be normal. The neurological 
examination pointed to a polyneuropathy (most probably drug-induced) and there was a 
suspicion of hepato-renal insufficiency and metabolic encephalopathy. In November, 2012, 
because of deterioration in the patient’s orientation and his febrile state, a suspicion of 
infectious origin of this condition arose. After some unsuccessful lumbar punctures, on the 
basis of findings during the MRI scan of the brain, the possibility of viral encephalitis, most 
probably herpes-encephalitis caused by HHV-6, in the temporal lobes was assumed (figs. 7A-
7B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Magnetic resonance imaging (MRI) of the brain on 19th post-transplant day: fluid attenuated inversion 
recovery (FLAIR) showing bilateral encephalitis in the temporal lobe, mainly in the region of the hippocampus 
(A). Diffusion weighted images with signal hyperintensities (B). 
B A 
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The patient was treated with gancyclovir, steroid and dexamethasone therapy intravenously. 
The patient’s condition improved after the introduction of the therapy. His status was vigil 
and partially disoriented; and he had slow psychomotorium. Pupil dilatations on both sides 
were reactive to light. His muscles were hypotonic over all extremities. No pathological 
reflexes or focal neurological signs could be observed. Lumbar puncture was then performed 
with minimal artificial bleeding (24.661M/lof red blood cells (RBCs), 20M/l of white blood 
cells (WBCs) and 1.22g/l of total protein). Cytology in CSF revealed an excessive amount of 
RBCs with a mixed cell count of WBCs dominated by segmented neutrophils. Real-time PCR 
tests proved negative for HSV-1/2, CMV, EBV and enteroviruses (Enterovirus RNA Kit, 
DiaPro; Milan, Italy) from plasma and cerebrospinal fluid samples. HHV-6 nested PCR was 
carried out and HHV-6 specific nested PCR gave positive results for the HHV-6 B variant in 
both sample types (Fig. 8). 
 
 
 
 
 
 
 
Figure 8. Detection of HHV-6 specific PCR product by agarose gelelectrophoresis (M-GeneRuler 100 bp DNA 
ladder; 1, negative control; 2, positive control (HHV-6 B); 3, HHV6B PCR product from a cerebrospinal fluid 
sample). 
Three days later, a deterioration in the patient’s condition was observed due to epileptic 
seizures. Partial seizures with oral and manual automatisms, confusion, and repetitive jerking 
movements in both extremities could be seen. Levetiracetam (500mg twice daily 
intravenously) was started and 2 days later the dose was increased to 1000mg twice daily and 
clobazam (10mg orally, 3 times a day) was introduced. In December, 2012, a lumbar puncture 
was performed; his CSF was water clear with 1M/l of RBCs, 1M/l of WBCs and 0.62g/l of 
total protein. Cytology testing indicated 1-2 RBCs, 18 lymphocytes and 2 macrophages. 
            M        1         2         3        M 
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HHV-6 nested PCR gave a positive result but the CSF was negative for HSV-1/2, CMV, 
EBV, and enteroviruses. Parenteral gancyclovir (500mg twice daily) therapy was given for 21 
days and followed by oral valgancyclovir (450mg twice daily) for four weeks. His mental and 
neurological state recovered and could be discharged from the transplant unit on 58th post-
transplant day (Fig. 9). 
 
Figure 9. Signal hyperintensities resolved on both sides of temporal lobe, consequent atrophia with dilatation of 
the sulcus and chambers. 
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5.DISCUSSION 
5.1. BLOODSTREAM INFECTIONS IN PATIENTS WITH HAEMATOLOGIC 
MALIGNANCY  
Although major advances in the care of cancer patients over the past several decades 
have resulted in improved survival rates, infectious complications remain a significant cause 
of morbidity and mortality. To successfully identify, treat, and prevent infections, a 
comprehensive understanding of risk factors that predispose to infection and of commonly 
encountered pathogens is necessary. In addition, clinicians must keep abreast of the changing 
epidemiology of infections in this population. As therapeutic modalities continue to evolve, as 
established pathogens become increasingly drug resistant, and as new pathogens are 
discovered, successful management of infections will continue to present challenges in the 
years to come. Febrile neutropenia is the most common complication of chemotherapy in 
patients with haematologic malignancy. This may have an influence on the chemotherapy and 
dose reduction applied; moreover, treatment delays may be observed if febrile neutropenia is 
present. These have an unfavourable long-term outcome in otherwise curable malignancy 
[62]. In patients with haematologic malignancy, bloodstream infections are the most 
important bacterial infections. Despite developments in microbiological diagnosis and 
antimicrobial therapy, these infections are responsible for the large proportion of nosocomial 
infections worldwide. In the early 1960s, the importance of bloodstream infection in 
neutropenic patients had been recognised, hence empirical treatment protocols were 
established for mainly Gram-negative bacteria, because at that time, the most common 
pathogens associated with bloodstream infections were Gram-negative bacilli [62]. Later, the 
spectrum of pathogens associated with BSI shifted from Gram-negative to Gram-positive 
bacteria due to the increased use of antibiotic prophylaxis and indwelling catheters allowing 
colonisations and infections. Nowadays, the most common pathogens isolated from the blood 
are coagulase-negative staphylococci and various antibiotic-resistant bacteria including 
multidrug resistant Gram-negative bacteria and VRE. In the majority of cases, the source of 
these infections is unknown in spite of various efforts to find them. The recognition of 
changes in the epidemiology of BSIs is very important in order to modify the antibiotic 
policy, because on the basis of these findings, we can reduce the infection-related morbidity 
and mortality [95, 104]. In our retrospective survey, during the 4-year study period, the 
incidence of bacteraemia was 20.4%. Similar findings were reported in the literature; 
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Klastersky et al. showed that the incidence of bacteraemia was 23% in cancer patients, while 
Viscoli et al. found that bacteraemia occurred in 29% of patients with febrile neutropenia [64, 
109]. Our findings were correlated with the above-mentioned literature data, because from the 
majority of blood culture bottles (13.7%), Gram-positive bacteria were isolated. Sixty-five 
percent of Gram-positive bacteria belonged to coagulase-negative staphylococci. However, in 
a study by Winston et al. in North America, Gram-negative bacteria (55.6%) were responsible 
for the majority of bacteraemia in febrile neutropenic patients [114].  At the same time, other 
researchers from Italy and France demonstrated that the most important isolates in 
neutropenic patients are Gram-positive bacteria, including coagulase-negative staphylococci 
or streptococci, while Gram-negative organisms including E. coli or Klebsiella spp., P. 
aeruginosa constituted a smaller portion of the isolates [40, 35]. In our case, the most 
frequently used empiric treatment in this patient group is piperacillin/tazobactam, or if the 
patient has colitis or the possibility of abdominal infection arises, imipenem or meropenem 
are frequently used antibiotics. Thus the increased incidence of Gram-positive bacteria can be 
accounted for by the empiric antibiotic treatment applied, while the presence of coagulase-
negative staphylococci may be attributed to the frequently used central venous catheters. The 
incidence of bacterial species in blood cultures can be influenced by the chemotherapy 
applied. In our case, 30% of patients with acute leukaemia received high dose Ara-C 
chemotherapy, and 15% and 12% of patients were treated with fludarabine and Ara-C plus 
idarubicin, respectively. On the basis of literature data, an increasing prevalence of Gram-
positive cocci in febrile neutropenic patients could be observed after high-dose cytarabine 
chemotherapy, and this was confirmed by our results [35]. Cordonnier et al. showed that the 
prevalence of staphylococci is higher than the prevalence of streptococci and enterococci in 
febrile neutropenic patients [35].  Similarly, our results bore this out, because among Gram-
positive bacteria the majority of the isolated strains were coagulase-negative staphylococci, 
6.7% and only 2.4% of Gram-positive bacteria belonged to Enterococcus spp. and beta-
hemolytic streptococci, respectively. 331 blood culture samples proved to be positive for 
coagulase-negative staphylococci, which had been collected from 161 febrile episodes of 149 
patients. In 50 febrile neutropenic episodes, coagulase-negative staphylococci were identified 
as the cause of fever, and these were confirmed with the coexistence of skin, soft tissue and 
central venous catheter-related infection. According to the clinical data and examination of 
the manifestations, the cause of the remaining 111 cases was probably due to contamination. 
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In the case of blood cultures that had positive results, Gram-negative bacteria were cultured, 
and the majority of these proved to be positive for E. coli (52%). The second most common 
isolate was P. aeruginosa (14%), while the third was Klebsiella spp (9.6%). Similar findings 
were obtained by Ramphal [95]. In this review, the results of four articles were analysed, and 
among Gram-negative organisms, the key pathogens were also E. coli, Klebsiella spp. and P. 
aeruginosa [95].   
Among rarely isolated bacteria, A. xylosoxidans, B. cepacia are usually associated with 
catheter-related sepsis, while S. maltophilia usually causes nosocomial bacteraemia [92]. 
However, the possible source of H. influenzae, Neisseria spp., Gemella spp. is the damaged 
oral mucosa. The identification of the isolated strain from bloodstream infection using 
traditional biochemical methods or automatic identification systems is sometimes 
unsuccessful because of the low biochemical activity of the isolated strain or if the isolated 
species cannot be found in the library of the automatic identification system, the result of 
identification will be misleading. In these cases, molecular methods like universal bacterial 
PCRs and sequencing or the use of MALDI-TOF, provide the opportunity to obtain the 
correct species name, as we saw in the case of bacteraemia caused by Nocardia sp., and A. 
xylosoxidans. Because of the fastidious or slow-growing nature of some rarely isolated 
bacteria, special nutriments and culture conditions are required for a successful culture test. 
Thus in the case of the possible presence of these opportunistic pathogens, the past medical 
history of the patients and communication between clinicians and microbiologists are 
essential to help confirm the presence of these bacteria. This situation may be observed in the 
case of nocardiosis in patients with cancer. Nocardiosis is most frequently described as an 
opportunistic infection in immunocompromised patients, especially in patients with depressed 
cell-mediated immunity. Pulmonary nocardiosis is the most common clinical presentation of 
this infection, while among the extrapulmonary forms, central nervous system (CNS) 
involvement is quite common [20, 107, 113]. Nocardia bacteraemia is a rarely described 
clinical entity and in the majority of patients (64%) concurrent pulmonary, cutaneous (28%) 
and CNS involvements (19%) may be observed [113]. In the case of disseminated 
nocardiosis, two or more organs are infected, and in the majority of cases, due to airway 
transmission the lung is also affected. Several publications described case reports about the 
presence of N. farcinica in various infections, but according to Christidou et al. up to 2004, 
only 11 English publications were found where N. farcinica bacteraemia was described [29]. 
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The majority of patients were male and had one or more predisposing factors, and the lung 
was the most common primary site of infection. The mortality rate was 41.7%, and a similarly 
poor outcome associated with N. farcinica was previously reported by Torres et al. [106]. 
General treatment recommendations for nocardiosis are difficult to provide due to the lack of 
controlled trials and variable in vitro antibiotic susceptibility patterns [113]. What is more, it 
is difficult to perform antimicrobial susceptibility testing because of the slow growing nature 
of several Nocardia sp., inoculum consistency and interpretation of the cut-off [101]. The 
treatment of N. farcinica infections is also problematic, because the majority of clinical 
isolates are multi-resistant, hence in our case the isolated strain was susceptible only to 
imipenem and amikacin. 
Because of the possible presence of unusual pathogens, such as anaerobic bacteria in 
bloodstream infections, the use of various blood culture bottles including anaerobic bottles 
should be considered. These confirmed those cases where a microbiological investigation 
revealed the presence of F. nucleatum in the blood cultures of four patients. In three cases, 
only one anaerobic bottle gave a positive signal. All the patients had clinical symptoms of 
sepsis; since the isolated F. nucleatum is not a member of the skin flora, its role as a possible 
contaminant was excluded. The mean number of days required for the blood culture bottles to 
become positive was 2.6 days (range 35 to 87 h). All four F. nucleatum strains proved to be 
susceptible to all the anti-anaerobic antibiotics tested (penicillin, amoxicillin/clavulanic acid, 
clindamycin, cefoxitin, imipenem and metronidazole). In each case, the underlying disease 
was haematological malignancy, acute myeloid or lymphoblastic leukaemia. Two patients 
(cases 1 and 3) received chemotherapy before the development of a febrile period, one of 
them had confirmed oropharyngeal mucositis, while with the other, there were no clinical 
symptoms of this, but the therapy used is known to make patients susceptible to the 
development of oral mucositis. In case 4, the patient had severe oropharyngeal mucositis 
without previous chemotherapy, while in case 2, the peritonsillar region and the soft palate 
were edematous. Fanourgiakis et al. [43] reported fifteen cases of bacteraemia caused by 
Fusobacterium spp. over a period of 6.5 years. Among these, thirteen patients were 
neutropenic, their mean age was 53 years, and the majority of them had underlying 
haematological malignancies and oral postchemotherapy mucositis. As oral mucositis was 
observed in almost all the patients, and this was the most likely source of the bacteraemia. 
This study also demonstrated that a relatively long incubation period (about 5 days) was 
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sometimes necessary to get positive signals in the case of anaerobic bottles. On the basis of 
literature data, in the 1960s and 1970s, the incidence of anaerobic bacteraemia increased due 
to improvements in anaerobic laboratory culture methods; and later this was followed by a 
decrease. Then between 1993 and 2004, the mean incidence of anaerobic bacteraemias once 
again increased [89].  
 
5.2. MONITORING THE PRESENCE OF CMV IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
Because of the increasing number of drugs associated with severe and prolonged cell-
mediated immunodeficiency, CMV infection is a major opportunistic infection among 
patients with malignant haematological diseases. The vast majority of publications have 
presented data about the occurrence of CMV reactivation and disease in haematological 
patients following stem cell transplantation - predominantly in an allogeneic setting-, hence 
little information is available about patients treated for haematological diseases without stem 
cell support [7, 25, 52, 86]. In our study, we retrospectively analysed epidemiological data 
and the incidence of CMV infection in patients with malignant haematological diseases over a 
6-year period. In the ASCT group, a higher rate of CMV infection (33.3%) was observed than 
that in the non-ASCT group (16.6%). Similarly, a higher rate of CMV infection (26-39%) was 
observed in autologous transplantation recipients in other international studies, mainly in 
patients who had received CD34+ selected autograft [44, 98]. Holmberg et al. also reported 
higher reactivation rates (22.6%) in patients who had received CD34+ selected autograft, than 
those in unselected cases (4.2%) during the first 100 post-transplant days [54]. However, a 
low risk of CMV infection was observed earlier in patients undergoing autologous stem cell 
transplantation [111].  In patients who had received pre-emptive anti-CMV treatment, CMV 
disease was not observed in association with ASCT [99, 37]. CMV pneumonia was identified 
in 2% of patients with ASCT and these were associated with CMV seropositivity before 
transplantation. Marchesi et al. also examined the rate of CMV reactivation after ASCT and 
he found that 11% of patients had required antiviral treatment because of CMV infection or 
end-organ diseases [81]. The majority of CMV reactivation occurred in patients with 
lymphoma (16%), while CMV PCR positivity was detected in 8% of myeloma patients [81].  
Al-Rawi et al. (2015) examined CMV reactivation with a CMV pp65 antigenemia test, and 
observed a CMV reactivation in 37 out of 210 patients (17.6%), and 94.6% of patients with a 
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positive antigenemia assay were treated with anti-CMV therapy. Due to the anti-CMV 
therapy, symptomatic CMV infection or end-organ disease was not observed, and the 
mortality was 29.7% in this group [3]. In our case, the majority of ASCT patients had 
asymptomatic reactivation. Eight patients (19%) suffered from symptomatic reactivation, 
while only 1 patient had CMV disease with 6225 copies/ml; and in this case, interstitial 
pneumonia and acute respiratory distress syndrome were demonstrated after a chest 
radiographic examination. The patient’s condition rapidly declined and the subject died two 
days later. The postmortem histological examination confirmed the diagnosis. As data 
published previously showed, the incidence of CMV pneumonia is 2-9% in ASCT recipients, 
with an extremely high mortality rate [7, 66, 68]. Marchesi and colleagues found a 
significantly higher transplant-related mortality rate in CMV reactivated patients (8.4%+/-
4.7% versus 1.7%+/-0.8%; p=0.047), while sex, diagnosis (NHL versus MM) and types of 
conditioning regimen did not display any significant differences [81]. Likewise in our 
observations, for ASCT and non-ASCT patients, no observed significant differences were 
found between the CMV PCR positive and negative groups according to age, sex (p=0.671, 
p=0.411), and mortality rate (p=0.429). On the basis of a statistical analysis, in the ASCT 
group, regarding the types of malignancies (MM, NHL, HL), no difference could be detected 
in the rate of CMV reactivation at a significance level of 5%, while differences were 
confirmed at a significance level of 10% (p=0.076 versus p=0.038). NHL patients with a B-
cell phenotype who had had a transplant were treated with rituximab as part of a pretransplant 
induction therapy, while only thirteen patients were treated with rituximab as part of a 
conditioning therapy. In a comparison of two types of conditioning treatment (BEAM+R-
BEAM versus melphalan), significant differences were found to exist on the prevalence of 
CMV reactivations (23.6% versus 42.3%; p=0.029). For R-BEAM, only one patient with 
NHL had a CMV positive PCR result. Because of the low number of cases, we did not look 
for a correlation between R-BEAM versus BEAM and CMV reactivation. Jain et al. (2016) 
analysed the results of CMV PCR in ASCT patients. In that study, 24% of patients were 
treated with rituximab as part of a pretransplant induction therapy or conditioning treatment. 
The rate of CMV PCR positivity was 2.9% in the case of the 239 patients who were 
examined. CMV viraemia was detected in seven patients, and three of them were treated with 
rituximab so this treatment for patients was not a significant risk factor for developing 
symptomatic CMV reactivation (p=0.34) [57].  Even though the number of patients with NHL 
was lower in our study, we obtained similar findings. In the case of patients with MM, no 
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significant differences were seen between the type of pretransplant induction treatment 
(bortezomib versus thalidomide) and a CMV positive/negative group (45% vs 46.7%; 
p=0.912). According to Marchesi et al, with MM patients treated with tandem ASCT, CMV 
reactivation after the first ASCT was more common when the induction treatment contained 
novel agents (odds ratio [OR]: 9.897; 95% confidence interval [CI]); p=0.021) [80]. It seems 
that high dose of dexamethasone applied in cases of patients undergoing this type of induction 
treatment has a detrimental effect on cell-mediated immunity. Still, proteasome inhibitors and 
immunomodulators may have an adverse effect on the T cell (NK, CD4+ and CD8+) count 
and function [12, 80, 90]. In our study, the majority of patients with lymphoid malignancies 
had CMV reactivation in the non-ASCT group, while the number of patients with myeloid 
malignant disease who suffered from a CMV infection was low (just 1 case). In the non-
ASCT group, fourteen patients had symptomatic CMV infections, and among these, CMV 
disease was observed in two cases (colitis and hepatitis). Similarly, the authors of several 
publications said that the risk for reactivation is highest among patients with 
lymphoproliferative diseases and those who were being treated for decreasing T-cell function 
with a drug such as alemtuzumab [5, 52, 59]. Han et al obtained similar findings when they 
examined CMV reactivation using a CMV pp65 antigenemia assay in patients with malignant 
haematological diseases [52]. They demonstrated that a significantly higher rate of 
reactivation could be detected in lymphoid malignancies than in myeloid ones. Another centre 
(Peter MacCallum Cancer Center in Melbourne, Australia) examined the presence of CMV 
DNA taken from whole blood in patients undergoing various chemotherapeutic regimens 
[hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate 
and cytarabine), fludarabine-containing regimens, alemtuzumab] and ASCT. The rate of 
CMV reactivation was 4.6, 4.2, 9.7, 2.6 and 50% in patients that had a fludarabine-based 
therapy, ASCT, hyperCVAD, rituximab treatment and alemtuzumab treatment, respectively 
[7]. Likewise, in our non-ASCT patient group with CMV reactivation, five patients were 
treated with alemtuzumab, two with a fludarabine-based therapy, and those who had the 
hyper-CVAD therapy did not have reactivation. Our findings are consistent with those found 
in observations published earlier [7, 13, 52, 99].  
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5.3. MONITORING THE PRESENCE OF HHV-6 IN PATIENTS WITH 
HAEMATOLOGIC DISEASES 
Autologous peripheral stem cell transplantation is a widely used procedure in the 
treatment of multiple myeloma, Hodgkin and non-Hodgkin lymphoma [102]. In this patient 
group, viral infection is one of the most important causes of post-transplant morbidity and 
mortality. In this setting, HHV-6 encephalitis represents a very rare type of viral infection and 
it is a severe life-threatening complication in ASCT recipients. Pagter et al. summarised 
several studies in which they analysed HHV-6 reactivation during haematopoietic stem cell 
transplantation. Eighteen studies were examined and, in the case of twelve of these, one 
month after haematopoietic stem cell transplantation, HHV-6 reactivation occurred. The 
incidence of HHV-6 reactivation ranged from 28% to 78% in allogeneic and autologous 
patients. Delayed platelet engraftment displayed a significant association with the presence of 
HHV-6 DNA [39]. Imbert-Marcille et al. studied 846 peripheral blood samples obtained from 
92 consecutive patients (526 from autologous and 320 from allogeneic transplant recipients) 
for HHV-6 DNA; 18.3% of these samples gave positive results. Similar to other studies, the 
incidence of active HHV-6 infection was 42.5 % after autologous transplantation (27/64) and 
also allogeneic (12/28) transplantation [56]. Ljungman et al. also confirmed that high HHV-6 
viral load was associated with the development of HHV-6 disease, myelosuppression and 
prolonged engraftment, mainly in megakaryocytic and erythroid cell lineages [71]. In addition 
to this, only patient 4 displayed clinical signs of infection due to HHV-6 reactivation. In our 
study, the number of HHV-6 positive samples was lower than that in previous studies; 
however, the number of patients analysed was also lower. Delayed engraftment was not 
observed in our study. In immunocompromised patients with signs of encephalopathy, a 
change in mental status and loss of short-term memory may help us to differentiate several 
causes not only intra-cerebral bleeding from thrombocytopaenia, direct toxicity of drugs, 
electrolite and other metabolic disturbances but infectious complications as well. Bommer et 
al. described encephalitis and pneumonitis caused by HHV-6 in a young patient with relapsed 
Hodgkin’s lymphoma that had undergone autologous stem cell transplantation. In that case, 
mental disturbances and convulsion were developed without abnormality in the first MRI 
image of the brain on the twelfth post-transplant day, while a CT scan of the chest revealed 
diffuse interstitial pneumonia on both sides of the lung. Bronchoalveolar lavage and CSF 
were positive for HHV-6 DNA. The patient was successfully treated with foscarnet followed 
by oral valgancyclovir for another six weeks [17]. We also had a patient with encephalitis due 
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to HHV-6 reactivation shortly after transplantation. Multiple EDTA blood and two CSF 
specimens taken from this patient gave positive HHV-6 PCR results, but no viral or bacterial 
pathogens were detected as a cause of encephalitis. Because of confirmed HHV-6 
encephalitis, parenteral gancyclovir was started followed by oral valgancyclovir. During this 
course of treatment, the neurological signs were resolved successfully with minimal short-
term memory dysfunction; and his haematological disease is now in complete remission. 
Similar to our findings, Imbert-Marcille et al. confirmed that active HHV-6 infection 
frequently occurred three or four weeks after transplantation [56]. However, lacking 
randomised clinical trials, treatment with gancyclovir, foscarnet or cidofovir is recommended 
for patients with HHV-6 encephalitis [118, 94]. In our case, gancyclovir treatment resolved 
the neurological signs with minimal sequelae. 
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6. CONCLUSIONS 
In this study our key aim was to evaluate the local epidemiology of most frequent 
infectious complications in immunocompromised patients, especially bacteraemia, 
CMV and HHV-6 infections in haematological patients, and following autologous 
stem cell transplantation. 
1. We evaluated the local occurrence of bacterial species that caused bloodstream infections 
in febrile neutropenic episodes between 2005 and 2008. In this study period among patients 
with febrile neutropenic episodes using microbiological culture, 20.4% of BC samples were 
positive, and in 67.1 % of positive BC samples Gram-positive bacteria were detected. The 
most frequent Gram-positive isolates were CNS (65%), S. aureus (10%) and the Enterecoccus 
species (6.7%). Here, CNS was identified in 331 cases and it was collected from 161 febrile 
neutropenic episodes of 149 patients. In 50 FN episodes, CNS was relevant as a causative 
agent of fever, because of the coexistence of skin, soft tissue and central venous catheter-
related infections. The remaining 111 cases that had a positive BC result for CNS were 
presumed to be due to contamination, hence it is necessary to stress importance of a well-
timed and precise sampling of a BC to avoid contamination. Gram-negative bacteria were 
isolated in 32.9 % of the positive BC results, and a high prevalence of E. coli (52%) was 
detected. This can be explained by the widespread use of indwelling catheters and more toxic 
high-dose chemotherapeutic regimens that can cause severe mucosal damage. 
 
2. In this study we characterised bloodstream infections caused by “unusual” pathogens and 
described some instructive cases that were caused by these interesting, rarely isolated 
pathogens. The identification of rarely isolated pathogens (A. xylosoxidans, B. cepacia, F. 
nucleatum and N. farcinica) not only required the use of traditional biochemical methods and 
automatic identification systems, but also special conditions for a successful culture; and in 
these cases bacterial PCRs and sequencing or MALDI-TOF led us to determine the exact 
microbial species. 
 
3. Out of the 271 patients with haematological malignancies all were tested using the CMV 
DNA method, and in 66 cases (24.4%) positive results were detected. Among CMV PCR 
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positive patients, 42 underwent ASCT. In the non-ASCT patient-group the risk of reactivation 
was highest among patients with lymphoproliferative disorders, and those that had received 
treatment associated with decreasing T-cell function (purine analogues, alemtuzumab). In the 
ASCT group according to the type of underlying disease (MM versus NHL patients), 
borderline significant differences were detected in the rate of CMV reactivation, and by 
comparing the type of conditioning regimen, it was found that significant differences exist 
across BEAM+R-BEAM versus Melphalan (p=0.029) regimens.   
 
4. After ASCT, 11.4% of the patients examined were found to be positive for HHV-6 after 
taking a sample of PB or CSF and applying the PCR method. Only one patient had been 
diagnosed with limbic encephalitis caused by HHV-6, and he was treated successfully with 
GCV. However without a randomised clinical trial, GCV, Foscarnet or CDV is recommended 
for patients with HHV-6 encephalitis. 
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